In April 2022, DS-8201a received Breakthrough Therapy Designation (BTD) from the US Food and Drug Administration (FDA) for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer (22). This evidence concerns the gene ERBB2 and breast carcinoma.